LGD-4033 (Ligandrol)

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM) and high selectivity for muscle and bone tissue over prostate and sebaceous glands. It activates anabolic pathways including increased nitrogen retention, enhanced protein synthesis, and glycogen storage in skeletal muscle. Unlike testosterone, it does not undergo aromatization or 5-alpha reduction, providing clean anabolic signaling without estrogenic or DHT-mediated side effects.

LGD-4033 is well-absorbed orally with high bioavailability. Time to peak plasma concentration is approximately 1.5 hours. The half-life of 24-36 hours supports once-daily dosing, with steady-state concentrations reached after approximately 5-7 days. It is metabolized hepatically but is non-methylated, resulting in a mild hepatic impact compared to oral anabolic steroids. Clearance is primarily renal and fecal.

• ✓Substantial lean body mass gains (clinical trial showed 1.21 kg gain in 21 days at just 1 mg/day)
• ✓Significant strength increases across all compound lifts
• ✓Enhanced muscle fullness and glycogen loading
• ✓Improved recovery between training sessions
• ✓Does not aromatize; no gynecomastia from estrogenic activity
• ✓Does not convert to DHT; lower androgenic side effect risk
• ✓Well-studied safety profile from human clinical trials
• ✓Excellent for both bulking and recomposition phases

• ⚠Dose-dependent testosterone suppression (significant at 5-10 mg doses)
• ⚠HDL cholesterol reduction (20-40% is common during cycle)
• ⚠Mild water retention in some users (more than RAD-140 or Ostarine)
• ⚠Potential mild headaches in the first week
• ⚠Lethargy and reduced libido in later weeks as suppression accumulates
• ⚠Temporary reduction in total testosterone, free testosterone, and SHBG
• ⚠All clinical trial subjects recovered hormone levels within 5 weeks of discontinuation

Contraindications

• 🚫Pre-existing liver or kidney disease
• 🚫Hormone-sensitive cancers
• 🚫Pregnant or breastfeeding women
• 🚫Males under 21 whose endocrine system is still developing
• 🚫Individuals with existing cardiovascular disease or severely compromised lipid profiles
• 🚫Those concurrently using other suppressive hormonal compounds without medical supervision

**PCT is required.** LGD-4033 produces significant suppression even at low doses. **Standard PCT (8-week cycle at 5-10 mg):** - Nolvadex (Tamoxifen) 20 mg/day for 4 weeks **Aggressive PCT (12-week cycle or high suppression confirmed by bloodwork):** - Nolvadex 40/40/20/20 mg over 4 weeks, OR - Clomid 50/25/25/25 mg over 4 weeks Wait 2-3 days after last dose before beginning PCT (half-life clears sufficiently). Confirm recovery with bloodwork 4-6 weeks post-PCT.

• 1.LGD-4033 is the SARM with the most human clinical data; this is a significant advantage for risk assessment
• 2.Expect some water retention, especially in the first 2-3 weeks; this is intracellular and not the same as estrogenic bloating
• 3.The water weight will come off within 1-2 weeks of stopping, revealing the true lean mass gained underneath
• 4.Keep sodium moderate and drink plenty of water to manage bloating
• 5.LGD-4033 is one of the best SARMs for someone focused on strength and mass
• 6.Do NOT stack with RAD-140 on your first SARM cycle; use one compound to assess individual response
• 7.Take progress photos and measurements; the scale alone is misleading due to water/glycogen fluctuations
• 8.Consider MK-677 as a non-suppressive stack partner for enhanced recovery and appetite

1. [1]Basaria S, et al. (2013). The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci.
2. [2]Phase II clinical trial data, Viking Therapeutics (VK5211).